Day: May 6, 2025

NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategy Completed $15.5M financing, extending projected cash runway into 1Q2027FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2025 and provided an update on recent business progress. Ron...

Updates 2025 OutlookNet Income of $12.2 Million for the First Quarter Net Income of $0.05 Per Diluted Common Share for the First Quarter AFFO of $0.35 Per Diluted Common Share for the First QuarterLITTLE ROCK, Ark., May 06, 2025 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced its results for the first quarter 2025. “We are off to a strong start at Uniti this year and are executing well on the goals we set out for 2025. Our core recurring strategic fiber revenue grew approximately 4% in the first quarter of 2025 when compared to the first quarter of 2024, consolidated bookings were up 40% during the first quarter when compared to the same period last year, and the capital intensity of our fiber business continues to decline. Despite the recent global economic volatility, we continue...

On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q 2025 Expanded atacicept development program across multiple autoimmune kidney diseases is underwayBRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2025. “We are rapidly approaching a significant Vera milestone with the upcoming primary endpoint results from the pivotal atacicept ORIGIN...

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025. “We continued to make progress towards our corporate development plans aimed at advancing life-saving therapies for viral and liver diseases,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “Over the past few months, we raised over $100M to begin our important Phase 2 study of ALG-000184 in chronic hepatitis B virus infection and we are on track to begin dosing by mid-2025 following recent positive correspondence with the FDA. Our...

Growth from Strategic Initiatives Drove Revenue Above the Midpoint of Guidance Book-to-Bill was Above One and Highest in Over Two Years MARLBOROUGH, Mass., May 06, 2025 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the first quarter ended March 31, 2025.  Three Months Ended March 31,        (In millions, except per share data and percentages)   2025       2024       Change  Revenue $ 227.8     $ 252.0       (10 )%Gross margin   39.4 %     38.7 %        Operating income $ 1.8     $ 19.1       (91 )%Operating margin   0.8 %     7.6 %        Net income $ 3.8     $ 24.1       (84 )%Earnings per diluted share $ 0.09     $ 0.52       (83 )%Non-GAAP Measures              Adjusted EBITDA* $ 32.7     $ 40.3       (19 )%Adjusted earnings per diluted share* $ 0.31     $ 0.50       (38 )%*Adjusted...

Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumors SAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 inverse agonist CRB-913 Dose escalation study on schedule for completion in Q4 2025 for the anti-αvβ8 integrin mAB-CRB-601 in solid tumorsNORWOOD, Mass., May 06, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2025. “During the first quarter of 2025, we continued to advance our pipeline by presenting encouraging CRB-701 Phase 1 solid tumor data from U.S. and U.K. sites at ASCO GU and initiating the...

VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic – KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 – CF, AATD, ocular complications of DEB, and aesthetics Strong balance sheet, ending the quarter with $765.3 million in cash and investments PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business update. “We were thrilled to receive VYJUVEK approval in Europe, and with the potential expansion to Japan later in the year, we continue to make tremendous progress on our goal of delivering profound long-term...

Sales and profitability down from last year’s exceptionally-strong first quarter due to lower demand in Rail Distribution; Infrastructure sales were up 5.0% year over year driven by Precast Concrete growth. Strong order rates across the portfolio increased backlog1 $51.3 million, or 27.6%, during the quarter to $237.2 million; Backlog1 up $15.0 million, or 6.7% over last year, with improved profitability mix. Maintaining full year financial guidance, with improving sales and profitability expected in second quarter.PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) — L.B. Foster Company (Nasdaq: FSTR), a global technology solutions provider of products and services for the rail and infrastructure markets (the “Company”), today reported its 2025 first quarter operating results. First Quarter 2025 Highlights  Three...

CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) — Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the first quarter ended March 30, 2025. Financial Highlights for the First Quarter 2025 vs. First Quarter 2024:Total revenue increased 6.4% or $10.6 million to $176.4 million; Same-restaurant sales increased 1.8%; Operating income increased $0.3 million to $10.4 million; Net income decreased $1.4 million to $4.0 million; Restaurant-Level Adjusted EBITDA(1) increased $0.3 million to $36.7 million; and Adjusted EBITDA(1) decreased $0.6 million to $21.2 million.(1) Adjusted EBITDA and Restaurant-Level Adjusted EBITDA are non-GAAP measures. Please see definitions and the reconciliations of these non-GAAP measures accompanying...

Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, sufficient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 was very productive for Cogent as our team focused on executing across our portfolio in preparation for three transformative data readouts this year. We look forward to reporting top-line results...